End-of-day quote
Dhaka S.E.
03:30:00 30/05/2024 am IST
|
5-day change
|
1st Jan Change
|
13.5
BDT
|
+1.50%
|
|
-1.46%
|
-28.57%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,404
|
2,230
|
2,186
|
2,036
|
1,975
|
Enterprise Value (EV)
1 |
2,243
|
2,216
|
2,249
|
2,078
|
2,008
|
P/E ratio
|
13.7
x
|
14.3
x
|
16.2
x
|
82.6
x
|
235
x
|
Yield
|
0.93%
|
-
|
2.08%
|
0.56%
|
-
|
Capitalization / Revenue
|
3.24
x
|
2.57
x
|
2.8
x
|
4.2
x
|
5.28
x
|
EV / Revenue
|
3.03
x
|
2.56
x
|
2.87
x
|
4.29
x
|
5.36
x
|
EV / EBITDA
|
11.7
x
|
9.21
x
|
10.7
x
|
27.7
x
|
29.9
x
|
EV / FCF
|
-14.1
x
|
-14.1
x
|
-25.6
x
|
25.9
x
|
128
x
|
FCF Yield
|
-7.08%
|
-7.09%
|
-3.9%
|
3.85%
|
0.78%
|
Price to Book
|
1.75
x
|
1.47
x
|
1.35
x
|
1.28
x
|
1.22
x
|
Nbr of stocks (in thousands)
|
1,13,737
|
1,13,737
|
1,13,737
|
1,13,737
|
1,16,205
|
Reference price
2 |
21.13
|
19.61
|
19.22
|
17.90
|
17.00
|
Announcement Date
|
27/11/19
|
06/12/21
|
06/12/21
|
13/12/22
|
22/11/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
660
|
740.7
|
866.1
|
782.2
|
484.7
|
374.5
|
EBITDA
1 |
162.7
|
191.2
|
240.7
|
209.2
|
74.93
|
67.05
|
EBIT
1 |
145.6
|
169.2
|
211.8
|
173.3
|
35.8
|
28.68
|
Operating Margin
|
22.06%
|
22.85%
|
24.46%
|
22.15%
|
7.39%
|
7.66%
|
Earnings before Tax (EBT)
1 |
151.5
|
180.8
|
217
|
169.3
|
31.72
|
24.57
|
Net income
1 |
98.49
|
155.2
|
156.2
|
134.7
|
25.17
|
8.407
|
Net margin
|
14.92%
|
20.96%
|
18.04%
|
17.22%
|
5.19%
|
2.24%
|
EPS
2 |
1.103
|
1.547
|
1.374
|
1.185
|
0.2166
|
0.0723
|
Free Cash Flow
1 |
-39.71
|
-158.9
|
-157.1
|
-87.68
|
80.07
|
15.65
|
FCF margin
|
-6.02%
|
-21.45%
|
-18.14%
|
-11.21%
|
16.52%
|
4.18%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
106.86%
|
23.34%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
318.06%
|
186.11%
|
Dividend per Share
|
-
|
0.1961
|
-
|
0.4000
|
0.1000
|
-
|
Announcement Date
|
25/10/18
|
27/11/19
|
06/12/21
|
06/12/21
|
13/12/22
|
22/11/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
62.5
|
41.7
|
32.3
|
Net Cash position
1 |
91.7
|
161
|
13.8
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.2986
x
|
0.5561
x
|
0.4819
x
|
Free Cash Flow
1 |
-39.7
|
-159
|
-157
|
-87.7
|
80.1
|
15.6
|
ROE (net income / shareholders' equity)
|
9.98%
|
12.9%
|
10.8%
|
8.57%
|
1.55%
|
0.52%
|
ROA (Net income/ Total Assets)
|
7.92%
|
7.54%
|
7.96%
|
5.97%
|
1.18%
|
0.95%
|
Assets
1 |
1,243
|
2,059
|
1,962
|
2,258
|
2,137
|
883.9
|
Book Value Per Share
2 |
11.60
|
12.10
|
13.40
|
14.30
|
14.00
|
14.00
|
Cash Flow per Share
2 |
1.030
|
1.410
|
0.1200
|
0.2000
|
0.2900
|
0.1000
|
Capex
1 |
113
|
182
|
309
|
200
|
39.7
|
30
|
Capex / Sales
|
17.06%
|
24.57%
|
35.68%
|
25.62%
|
8.19%
|
8.02%
|
Announcement Date
|
25/10/18
|
27/11/19
|
06/12/21
|
06/12/21
|
13/12/22
|
22/11/23
|
|
1st Jan change
|
Capi.
|
---|
| -28.57% | 13.36M | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | -5.52% | 206B | | +6.17% | 164B | | -0.45% | 162B |
Other Pharmaceuticals
|